| Execution period | Valid till December 31, 2028 |
|---|
NSE filing, NSE: VR. Summary written from the filing by ALFA Finder's alert engine.
V R Infraspace Ltd: key numbers
- Share price
- ₹93.95
- Market cap
- ₹83.43 Cr
- Revenue (annual)
- ₹74.44 Cr
- Net profit (annual)
- ₹3.92 Cr
- P/E (TTM)
- 21.3×Sector 34.5×
- Promoter holding
- 72.97%
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from V R Infraspace Ltd
All →V R Infraspace Other Announcement
V R Infraspace submitted its Integrated Governance Filing for the quarter ended September 30, 2026. The filing reports nil investor complaints and no fines or penalties.
V R Infraspace Bags ₹1.45 Cr Order from Superintending Engineer’s office, Rajkot
V R Infraspace Limited received a Rs. 1.45 Crore work order from the Superintending Engineer’s office, Rajkot, for road improvement work.
- Value
- ₹1.45 Cr
- From
- Superintending Engineer’s office (Panchayat R & B Circle-2), Rajkot
V R Infraspace Annual General Meeting
V R Infraspace Limited concluded its 11th Annual General Meeting on September 29, 2026, through video conferencing, covering ordinary and special business resolutions for shareholders.
V R Infraspace Annual General Meeting
V R Infraspace Limited issued notice for its 11th Annual General Meeting on September 29, 2026, via video conferencing. The agenda includes financial adoption and various approvals.
V R Infraspace Debt & Borrowing: ₹5 Cr
V R Infraspace Ltd approved a ₹5 Crore corporate guarantee for its subsidiary, Daxon Realty Ltd, to secure a loan facility from Indian Bank.
- Value
- ₹5.00 Cr
V R Infraspace Merger & Restructuring
V R Infraspace Limited has withdrawn its proposed acquisition of the remaining 5% stake in subsidiary Daxon Realty Limited. The company's stake remains at 66%.
Other regulatory approval announcements
All →Vedavaag Systems Regulatory Approval
Vedavaag's WOS received IRDAI Certificate of Registration to act as Direct Life & General Insurance Broker. The group enters regulated insurance broking activity.
Hikal Regulatory Approval
Hikal's Bengaluru API facility received a Swissmedic GMP Certificate of Compliance. The certification supports wider access to European and other regulated markets.
Sun Pharmaceutical Industries Regulatory Approval
Sun Pharma gained US FDA approval for ILUMYA in adults with active psoriatic arthritis. The approval extends the drug's psoriasis use, with no financial value stated.
RNFI Services Regulatory Approval
RNFI received RBI no-objection to acquire control of Smart Payment Solutions Private Limited. Remaining tranches may proceed, but no transaction value is disclosed.
Shalby Regulatory Approval
Shalby Hospital, Jabalpur received CMHO permission to resume normal operations, including patient admissions, on its previously affected floor. The hospital has now fully resumed healthcare services.
Elantas Beck India Regulatory Approval
Elantas Beck India's GPCB permanently revoked the closure direction on its Ankleshwar plant. The facility can keep operating, subject to compliance conditions.